Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1119-1127

  Mittendorf, Elizabeth A ^a   Ballman, Karla V ^c   McCall, Linda M ^d   Yi, Min ^a   Sahin, Aysegul A ^a   Bedrosian, Isabelle ^a   Hansen, Nora ^e   Gabram, Sheryl ^f   Hurd, Thelma ^b   Giuliano, Armando E ^g   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CENTER; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MICROMETASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE; VERY ELDERLY; BREAST NEOPLASMS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SENTINEL LYMPH NODE BIOPSY; UNITED STATES; YOUNG ADULT;

ESTROGEN RECEPTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY; UNITED STATES; YOUNG ADULT;

EID: 84927169096     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2958     Document Type: Article

References (33)

1. Lyman GH, Temin S, Edge SB, et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365-1383, 2014
2. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
3. Lyman GH, Giuliano AE, Somerfield MR, et al: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703-7720, 2005
4. Giuliano AE, Hawes D, Ballman KV, et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385-393, 2011
5. Weaver DL, Ashikaga T, Krag DN, et al: Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412-421, 2011
6. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Handbook. New York, NY, Springer, 2002
7. Edge SB, Compton CC, Fritz AG, et al: (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
8. Breslin TM, Cohen L, Sahin A, et al: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18: 3480-3486, 2000
9. Hunt KK, Yi M, Mittendorf EA, et al: Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250: 558-566, 2009
10. Lambert LA, Ayers GD, Hwang RF, et al: Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13: 310-320, 2006
11. Mittendorf EA, Sahin AA, Tucker SL, et al: Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol 15:3369-3377, 2008
12. Yi M, Mittendorf EA, Cormier JN, et al: Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: Time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29:4654-4661, 2011
13. Mittendorf EA, Hunt KK: Significance and management of micrometastases in patients with breast cancer. Expert Rev Anticancer Ther 7:1451-1461, 2007
14. Galimberti V, Cole BF, Zurrida S, et al: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol 14:297-305, 2013
15. Giuliano AE, Hunt KK, Ballman KV, et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 305:569-575, 2011
16. Giuliano AE, McCall L, Beitsch P, et al: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426-432, 2010
17. Theriault RL, Litton JK, Mittendorf EA, et al: Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11:325-331, 2011
18. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
19. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
20. McArthur HL, Mahoney KM, Morris PG, et al: Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468, 2011
21. Mamounas EP, Tang G, Fisher B, et al: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677-1683, 2010
22. ClinicalTrials.gov: RxPONDER: A phase III, randomized clinical trial of standard adjuvant endocrine therapy - chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less. http://clinicaltrials.gov/show/ NCT01272037
23. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
24. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
25. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
26. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
27. Dawood S, Hu R, Homes MD, et al: Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat 126:185-192, 2011
28. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol 26:2373-2378, 2008
29. Bagaria SP, Ray PS, Sim MS, et al: Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg 149:125-129, 2014
30. Jeruss JS, Mittendorf EA, Tucker SL, et al: Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26:246-252, 2008
31. Mittendorf EA, Jeruss JS, Tucker SL, et al: Validation of a novel staging system for diseasespecific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29:1956-1962, 2011
32. Fanshawe TR, Lynch AG, Ellis IO, et al: Assessing agreement between multiple raters with missing rating information, applied to breast cancer tumour grading. PLoS One 3:e2925, 2008
33. Rakha EA, El-Sayed ME, Lee AH, et al: Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153-3158, 2008